CARDURION PHARMACEUTICALS LLC has a total of 27 patent applications. It increased the IP activity by 40.0%. Its first patent ever was published in 2017. It filed its patents most often in United States, Canada and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are CHENGDU EASTON BIOPHARMACEUTICALS CO LTD, CLAROCHEM IRELAND LTD and CRYSTAL PHARMACEUTICAL SUZHOU CO LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 5 | |
#2 | Canada | 4 | |
#3 | WIPO (World Intellectual Property Organization) | 4 | |
#4 | Australia | 3 | |
#5 | EPO (European Patent Office) | 3 | |
#6 | Taiwan | 2 | |
#7 | Brazil | 1 | |
#8 | China | 1 | |
#9 | Colombia | 1 | |
#10 | Israel | 1 | |
#11 | Republic of Korea | 1 | |
#12 | Singapore | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Name | Total Patents |
---|---|---|
#1 | Shiokawa Zenyu | 12 |
#2 | Shirai Junya | 12 |
#3 | Matsunaga Nobuyuki | 12 |
#4 | Okawa Tomohiro | 12 |
#5 | Nakahata Takashi | 12 |
#6 | Miyamoto Yasufumi | 12 |
#7 | Shibuya Akito | 12 |
#8 | Wang Xiaolun | 8 |
#9 | Yoshikawa Takeshi | 8 |
#10 | Okamoto Rei | 8 |
Publication | Filing date | Title |
---|---|---|
WO2020068854A1 | Aminopyrimidine compound | |
BR112020021153A2 | meglumine salts of thienopyrimidines | |
CA3058182A1 | Heterocyclic compound | |
CA3030021A1 | Methods for treatment of heart failure |